Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Systemic autoimmune diseases are characterized by the failure of the immune system to
differentiate self from non-self. These conditions are associated with significant morbidity …

Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods,
together with associated computational tools and the growing availability of public data …

Sepsis arises from diverse and incompletely understood dysregulated host response
processes following infection that leads to life-threatening organ dysfunction. Here we …

Dexamethasone (DEX) is the first drug to show life-saving efficacy in patients with severe
coronavirus disease 2019 (COVID-19), while DEX is associated with serious adverse …

There has been an important change in the clinical characteristics and immune profile of
Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the …

Although the exact prevalence of post-COVID-19 condition (also known as long COVID) is
unknown, more than a third of patients with COVID-19 develop symptoms that persist for …

Critically ill patients in intensive care units experience profound alterations of their gut
microbiota that have been linked to a high risk of hospital-acquired (nosocomial) infections …

With a global tally of more than 500 million cases of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infections to date, there are growing concerns about the post …

Myeloid cells are a significant proportion of leukocytes within tissues, comprising
granulocytes, monocytes, dendritic cells, and macrophages. With the identification of various …